GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Type 2 Diabetes
- Registration Number
- NCT00252876
- Lead Sponsor
- AstraZeneca
- Brief Summary
This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
- Provision of a written informed consent
- Men or women who are >=18 years of age
- Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
- Completed the last two visits of randomized treatment period in GALLANT 2/22, 5, 7, 8 or 14 studies.
Exclusion Criteria
- Type 1 diabetes
- New York Heart Association heart failure Class III or IV
- Treatment with chronic insulin
- History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
- History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
- Creatinine levels above twice the normal range
- Creatine kinase above 3 times the upper limit of normal
- Previous enrollment in this long-term extension study
- Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs (blood pressure and pulse), body weight
- Secondary Outcome Measures
Name Time Method C-reactive protein Responder rates and proportion of patients on tesaglitazar who reach pre-specified target levels for triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol Pharmacodynamic: fasting plasma glucose, glycosylated hemoglobin A1c, lipid variables (triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol) Central obesity (waist circumference, hip circumference, waist/hip ratio)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of tesaglitazar in improving insulin sensitivity in type 2 diabetes patients?
How does tesaglitazar compare to other PPAR agonists like pioglitazone in long-term safety and efficacy for type 2 diabetes management?
Which biomarkers correlate with sustained glycemic control in type 2 diabetes patients treated with tesaglitazar 1 mg over 104 weeks?
What are the long-term adverse event profiles of tesaglitazar in type 2 diabetes patients with comorbid cardiovascular conditions?
How does the safety data from NCT00252876 influence the development of other PPAR dual agonists by AstraZeneca and competitors for diabetes treatment?
Trial Locations
- Locations (1)
Research Site
🇻🇳Ho Chi Minh, Vietnam
Research Site🇻🇳Ho Chi Minh, Vietnam